The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
350
Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).
The NPI-C (de Medeiros et al 2010) is a validated and reliable behavioral measure that assesses psychopathology in dementia subjects. It evaluates 14 neuropsychiatric disturbances common in dementia.Higher scores on the NPI-C are associated with a greater clinical severity of symptoms. The NPI-C Agitation and Aggression score ranges from 0-63. The analysis of the NPI-C A+A score was performed on the mITT population.
Time frame: Week 12
Change From Baseline in Modified-ADCS-CGIC Agitation Scores
The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) is a widely used scale for the global assessment of change in AD trials.It is a 7-point Likert scale that ranges from marked improvement scored as 1 to marked worsening scored as 7, with no change scored as 4. The range is from 1 to 7. Higher scores indicate worsening agitation.
Time frame: Week 12
Change From Baseline in NPI Total Scores
The NPI (Cummings et al 1994) is a behavioral measure that assesses psychopathology in dementia subjects. It evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, nighttime behavior disturbances, and appetite and eating abnormalities. Higher scores on the NPI are associated with greater frequency and severity of symptoms. The scale range is 0-144.
Time frame: Week 12
Change From Baseline in MMSE Scores
The Mini-Mental State Exam (MMSE) (Folstein et al 1975) is a brief cognitive test assessing general cognitive function that has been employed in numerous clinical trials of products approved for the treatment of AD. The score can range from 0 to 30, with lower scores indicating greater impairment in function.
Time frame: Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
TransitionTIL Investigational Site
Birmingham, Alabama, United States
TransitionTIL Investigational Site
Phoenix, Arizona, United States
TransitionTIL Investigational Site
Phoenix, Arizona, United States
TransitionTIL Investigational Site
Encino, California, United States
TransitionTIL Investigational Site
Escondido, California, United States
TransitionTIL Investigational Site
Fresno, California, United States
TransitionTIL Investigational Site
Irvine, California, United States
TransitionTIL Investigational Site
Long Beach, California, United States
TransitionTIL Investigational Site
Los Alamitos, California, United States
TransitionTIL Investigational Site
Los Angeles, California, United States
...and 60 more locations
Change From Baseline in ADCS-ADL Scores
The Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (Galasko et al 1997) is a functional assessment that measures instrumental and basic activities of daily living. The total score for the 23-item ADCS-ADL ranges from 0 to 78 points, with lower scores indicating greater impairment in function.
Time frame: Week 12